Governance ImprovementsDHT has improved its governance structure by requiring independent trustees to take at least half their retainer in equity, aligning interests with shareholders.
Management ConfidenceAli Hedayat, with extensive experience from Goldman Sachs and hedge funds, is involved in DHT's strategy and owns shares personally, indicating confidence in the company's direction.
Regulatory ApprovalsCASGEVY has been approved by the FDA and EMA for use in sickle cell disease and transfusion-dependent beta-thalassemia, indicating strong regulatory backing.